Arrhythmic Mitral Valve Prolapse: Risk Factors, Pathophysiology and Risk Stratification for Cardiac Arrhythmias

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Electrophysiology and Cardiovascular Physiology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 647

Special Issue Editor

1. Department of Medicine, University of Melbourne, Melbourne, VIC 3010, Australia
2. Department of Cardiology, Austin Health, Melbourne, VIC 3084, Australia
3. Department of Cardiology, Northern Health, Melbourne, VIC 3076, Australia
Interests: sudden cardiac death; mitral valve prolapse; cardiac arrhythmia; atrial fibrillation; stroke

Special Issue Information

Dear Colleagues,

Mitral valve prolapse is a common valvular disorder affecting about 2–3% of the general population. While the majority of cases have benign outcomes, there is a specific subset of patients for whom mitral valve prolapse is associated with malignant ventricular arrhythmias and sudden cardiac death. This specific patient subset is classed as having arrhythmic mitral valve prolapse. Sudden cardiac arrest can occur in young patients with mitral valve prolapse, which can be a devastating event. The link between sudden cardiac death and mitral valve prolapse is increasingly being recognised. However, the underlying pathophysiology and risk factors are incompletely understood and risk stratification methods remain poorly defined.

This Special Issue will focus on defining the risk factors, exploring the pathophysiology in arrhythmic mitral valve prolapse, and describing the current challenges in risk stratification for sudden cardiac death in this cohort of patients.

Dr. Han Lim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • mitral valve prolapse
  • mitral annular disjunction
  • arrhythmia
  • sudden cardiac death
  • risk stratification

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


13 pages, 1475 KiB  
Arrhythmic Mitral Valve Prolapse Syndrome and Ventricular Arrhythmias: A Comprehensive Review and the Role of Catheter Ablation
by Ehsan Mahmoodi and Haris M. Haqqani
J. Cardiovasc. Dev. Dis. 2024, 11(7), 218; - 10 Jul 2024
Viewed by 268
Mitral valve prolapse (MVP) affects 2–3% of the general population, and despite its benign prognosis overall, it is associated with sudden death in a small subset of patients. The term “arrhythmic MVP syndrome” (AMVPS) refers to the presence of frequent or complex ventricular [...] Read more.
Mitral valve prolapse (MVP) affects 2–3% of the general population, and despite its benign prognosis overall, it is associated with sudden death in a small subset of patients. The term “arrhythmic MVP syndrome” (AMVPS) refers to the presence of frequent or complex ventricular arrhythmias, commonly reported in female patients with a stereotypical phenotype including bileaflet myxomatous disease, ECG repolarisation abnormalities in inferior leads, mitral annular disjunction, and significant fibrosis in the inferolateral LV and papillary muscles. Modern imaging technologies have led to the identification of new risk factors that have been implemented in recent risk stratification guidelines; however, screening for patients with MVP who are at risk of sudden cardiac death (SCD) remains challenging. In addition, there is a limited amount of data on the outcomes of different treatment approaches in AMVP and no specific indication for targeted or disease-modifying therapies within current guidelines. Potential arrhythmic substrates in patients with AMVP syndrome have been the subject of interest in previous studies, with areas consisting of fibrosis at the papillary muscle level and the Purkinje system. Premature ventricular contractions (PVCs) originating from these areas have been shown to play an important role as triggers for ventricular fibrillation and SCD in patients with AMVP. Catheter ablation has emerged as a potential treatment modality in patients with MVP and ventricular arrhythmias (VAs), targeting arrhythmic substrates and triggering PVC foci. The aim of this review is to explore the role of catheter ablation in treating patients with AMVP. Full article
Back to TopTop